Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
|
|
Lucid Diagnostics Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/26/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 06/02/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 06/01/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 05/22/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 05/01/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/01/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/19/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 04/05/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 04/03/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 03/24/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"Execution Version",
"VOTING AGREEMENT AND STOCKHOLDER CONSENT VOTING AGREEMENT, dated as of March 21, 2023 , by and between Lucid Diagnostics Inc., a Delaware corporation with offices located at 360 Madison Avenue, 25th Floor, 10017 and PAVmed Inc., a Delaware corporation with offices located at 360 Madison Avenue, 25th Floor, 10017 . WHEREAS, the Company and a certain investor have entered into a Securities Purchase Agreement, dated as of March 13, 2023 , pursuant to which, among other things, the Company has agreed to issue and sell to the Investor and the Investor has agreed to purchase certain senior secured convertible notes of the Company , which will be convertible into shares of the Company’ s common stock, $0.001 par value per share , in accordance with the terms of the Notes; WHEREAS, as of the date ..." |
|
| 03/24/2023 |
SC 13G/A
| Ayrton Capital LLC reports a 4.9% stake in LUCID DIAGNOSTICS INC. |
| 03/23/2023 |
SC 13G
| Ayrton Capital LLC reports a 10% stake in LUCID DIAGNOSTICS INC. |
| 03/22/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 03/14/2023 |
8-K
| Quarterly results|
Docs:
|
"[FORM OF SENIOR SECURED CONVERTIBLE NOTE] NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL TO THE HOLDER , IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE ...",
"8-K Filing”). From and after the filing of the 8-K Filing, the Company shall have disclosed all material, non-public information provided to any of the Buyers by the Company or any of its Subsidiaries or any of their respective officers, directors, employees or agents in connection with the transactions contemplated by the Transaction Documents. In addition, effective upon the filing of the 8-K Filing, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, affiliates, employees or agents, on the one hand, and any of the Buyers or any of their affiliates, on the other hand, that is then in effect shall terminate.",
"W I T N E S S E T H : WHEREAS, the Company and each party listed as a “Buyer” on the Schedule of Buyers attached to the Securities Purchase Agreement are parties to the Securities Purchase Agreement, pursuant to which the Company shall be required to sell, and the Buyers shall purchase or have the right to purchase senior secured convertible notes of the Company issued pursuant thereto ; WHEREAS, certain Grantors from time to time may execute and deliver one or more guarantees in form and substance acceptable to and in favor of the Collateral Agent, for the ratable benefit of itself and the Noteholders, with respect to the Company’ s obligations under the Securities Purchase Agreement, the Notes and the other “Transaction Documents” ; WHEREAS, it is a condition precedent to the Buyers’ obl...",
"[Signatures continue on following page]",
"Lucid Diagnostics Provides Business Update and Fourth Quarter and Full Year 2022 Financial Results 4Q22 and projected 1Q23 EsoGuard test volume increases 8 and 36 percent sequentially and 288 and 300 percent annually." |
|
| 03/13/2023 |
8-K
| Unregistered Sales of Equity Securities, Material Modifications to Rights of Security Holders, Amendments to Articles of Inco...|
Docs:
|
"LUCID DIAGNOSTICS INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, Lishan Aklog, does hereby certify that: 1. He is the Chief Executive Officer of Lucid Diagnostics Inc., a Delaware corporation . 2. The Corporation is authorized to issue 20,000,000 shares of preferred stock. 3. The following resolutions were duly adopted by the board of directors of the Corporation : WHEREAS, the certificate of incorporation of the Corporation provides for a class of its authorized stock known as preferred stock, consisting of 20,000,000 shares, $0.001 par value per share, issuable from time to time in one or more series; WHEREAS, the Board of Directors is authorize...",
"Form of Registration Rights Agreement" |
|
| 02/10/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 02/10/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 01/18/2023 |
8-K
| Quarterly results |
| 12/07/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 12/02/2022 |
SC 13D/A
| PAVmed Inc. reports a 73.7% stake in Lucid Diagnostics Inc. |
| 12/02/2022 |
8-K
| Unregistered Sales of Equity Securities, Financial Statements and Exhibits Interactive Data|
Docs:
|
"SIXTH AMENDMENT TO MANAGEMENT SERVICES AGREEMENT Reference is made to the Management Services Agreement , dated as of May 12, 2018, by and between PAVmed Inc., a Delaware corporation and Lucid Diagnostics Inc., a Delaware corporation . WHEREAS, as set forth in Section 3 of the Agreement, the parties have considered in good faith an adjustment to the Service Fee and hereby wish to amend the Agreement to reflect such adjustment as set forth herein. NOW, THEREFORE, in consideration of the foregoing and the mutual agreements hereinafter set forth, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereby agree as follows: 1. Amendment. Effective July 1, 2022, Section 3 of the Agreement is hereby deleted in its entirety and repl...",
"PAYROLL AND BENEFIT EXPENSE REIMBURSEMENT agreement" |
|
| 11/14/2022 |
8-K
| Quarterly results |
| 08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/15/2022 |
8-K
| Quarterly results |
| 08/02/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/25/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 07/22/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 06/22/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/16/2022 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 05/16/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/12/2022 |
8-K
| Quarterly results |
| 05/09/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 05/02/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
|
|
|